1. Home
  2. MU vs JNJ Comparison

MU vs JNJ Comparison

Compare MU & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MU

Micron Technology Inc.

N/A

Current Price

$405.79

Market Cap

444.2B

Sector

Technology

ML Signal

N/A

Logo Johnson & Johnson

JNJ

Johnson & Johnson

N/A

Current Price

$244.13

Market Cap

589.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MU
JNJ
Founded
1978
1886
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
444.2B
589.2B
IPO Year
1994
2003

Fundamental Metrics

Financial Performance
Metric
MU
JNJ
Price
$405.79
$244.13
Analyst Decision
Strong Buy
Buy
Analyst Count
31
18
Target Price
$359.45
$229.89
AVG Volume (30 Days)
24.0M
7.0M
Earning Date
01-01-0001
04-21-2026
Dividend Yield
0.11%
2.14%
EPS Growth
984.29
90.50
EPS
4.60
11.03
Revenue
$30,391,000,000.00
N/A
Revenue This Year
$112.37
$6.63
Revenue Next Year
$30.09
$7.23
P/E Ratio
$90.98
$22.06
Revenue Growth
49.55
N/A
52 Week Low
$61.54
$141.50
52 Week High
$455.50
$251.71

Technical Indicators

Market Signals
Indicator
MU
JNJ
Relative Strength Index (RSI) 52.45 57.85
Support Level $363.90 $201.37
Resistance Level $443.72 $251.71
Average True Range (ATR) 18.88 4.12
MACD -2.53 -1.33
Stochastic Oscillator 55.95 49.94

Price Performance

Historical Comparison
MU
JNJ

About MU Micron Technology Inc.

Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.

About JNJ Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Share on Social Networks: